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http://www.biomedcentral.com/1471-2296/15/121RESEARCH ARTICLE Open AccessProstate specific antigen testing is associated with
men’s psychological and physical health and their
healthcare utilisation in a nationally representative
sample: a cross-sectional study
Evelyn M Flahavan1*†, Frances J Drummond2†, Kathleen Bennett1, Thomas I Barron1 and Linda Sharp2Abstract
Background: Prostate cancer incidence has risen considerably in recent years, primarily due to Prostate Specific
Antigen (PSA) testing in primary care. The objective of this study was to investigate associations between PSA testing
and the psychological and physical health, and healthcare utilisation of men in a population where PSA testing is
widespread.
Methods: A cross-sectional study was carried out in a population-representative sample of men ≥50 years enrolled in
The Irish Longitudinal Study on Ageing (TILDA). TILDA participants underwent structured interviews, health assessments
and completed standardised questionnaires. Men were classified as ever/never having received a PSA test. Multivariate
logistic regression (Odds Ratios (OR) and 95% Confidence Intervals (CI) was used to determine associations between
PSA testing, and men’s psychological and physical health and healthcare utilisation.
Results: This analysis included 3,628 men, 68.2% of whom ever had a PSA test. In adjusted analysis, men with
sub-threshold depression were significantly less likely to have had a PSA test, (OR = 0.79, 95% CI 0.64-0.97). Likelihood
of having a PSA test was inversely associated with anxiety, but this was not significant (OR = 0.79, 95% CI 0.57-1.09).
Frailty (OR = 0.61, 95% CI 0.31-1.05) and eligibility for free primary care (OR = 0.63, 95% CI 0.52-0.77) were also inversely
associated with PSA testing. Positive associations were observed between PSA testing and more chronic illnesses
(OR = 1.11, 95% CI 1.05-1.19), more primary care visits (OR = 1.03, 95% CI 1.01-1.05) and preventative health practices,
including cholesterol testing and influenza vaccination (OR = 1.35, 95% CI 1.13-1.60).
Conclusions: Men’s psychological and physical health and their healthcare utilisation are associated with PSA testing
in primary care. The association between poorer psychological health, in particular sub-threshold depression, and
reduced likelihood of PSA testing in primary care requires further investigation. These findings may have wider
implications for other cancer screening.Background
Prostate cancer incidence has increased in the last two
decades, due to increasing prostate specific antigen
(PSA) testing and subsequent prostate biopsy [1]. Results
from two large randomised controlled trials, have not
definitively answered the question regarding the benefit
of PSA testing on mortality [2,3]. Despite this, the rate* Correspondence: flahavae@tcd.ie
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unless otherwise stated.of PSA testing in Ireland is high [4] and the number of
PSA tests performed continues to rise [5]. The majority
of PSA tests originate in general practice [4,5]. This op-
portunistic testing has led to an increase in prostate
cancer incidence, younger age at diagnosis and a shift to-
wards more localized disease [5,6]. Increased prostate
cancer detection has important consequences for men’s
quality-of-life [7,8]. There is no consensus between guide-
lines internationally on the use of PSA testing [9,10] and
PSA testing of asymptomatic men is not a national policy
in Ireland [11,12]. It is therefore important to understandal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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practice.
Psychological health negatively impacts breast, cervical
and colorectal cancer screening [13,14]. Its impact on
cancer screening in men [15] and on PSA testing has re-
ceived little attention, however, and results have been
conflicting due to small sample sizes and different mea-
sures used [16-18]. In addition, a small number of stud-
ies have recently reported that markers of healthcare
utilisation influenced whether men have PSA tests and
other cancer screening [17,19,20].
Our objective was to investigate, at the population
level, associations between PSA testing and men’s psy-
chological and physical health and their health services
utilisation.
Methods
Setting
Ireland has a mixed public-private healthcare system.
Approximately one-third of the population are eligible
for the state-funded General Medical Services (GMS)
Scheme, as determined by means-test and age [21],
which entitles them to free General Practitioner (GP)
and hospital visits and prescriptions for a small fee per
item. GPs are reimbursed for GMS patients by the Health
Services Executive. Approximately half the population
have private health insurance (PHI). However, most insur-
ance plans do not cover GP visits, and patients pay be-
tween €50 and 60 per visit.
Study population
This study population consisted of males aged ≥50 years
participating in wave 1 (2009–2011) of The Irish Longitu-
dinal Study on Aging (TILDA) [22]. TILDA is a study of
the health, lifestyle and financial situation of a population-
representative sample of people aged ≥50 years involving
Computer Aided Personal Interview (CAPI) in partici-
pants’ homes, a Self-Completion Questionnaires (SCQ)
and comprehensive health assessment (HA) in one of two
health centres. Where travel to health centres was unfeas-
ible (~10% of participants), nurses performed the HA in
participant’s homes (Additional file 1). TILDA was ap-
proved by the Faculty of Health Sciences Research Ethics
Committee of Trinity College Dublin. Potential partici-
pants, who were unable to give consent due to dementia
or cognitive impairment, were excluded.
Outcome variable
The main outcome variable was ever having had a PSA
test. Men were included if they gave a definitive answer
to the CAPI question asking had they ever had “a PSA
blood test to screen for prostate cancer”. Men who
responded “don’t know” or declined to answer were ex-
cluded (n = 116).Covariates
Healthcare utilisation
The self-reported healthcare utilisation variables recorded
were i) number of GP visits in the previous year; eligibility
for GMS [23] (yes/no), ii) cholesterol testing (ever/never),
iii) influenza vaccination (ever/never), and iv) number of
regular medicines (prescription/other) including chronic
cardio-preventative medication, statins, and aspirin (yes/no)
classified using WHO ATC Classification.
Three scales were used to measure psychological health;
depression was assessed using the Centre for Epidemio-
logic Studies Depression (CES-D) scale (scored as 0–7 not
depressed; 8–15 sub-threshold; ≥16 case-level depression
[24]); anxiety was assessed using the Hospital Anxiety and
Depression Scale (HADS-A): (scored as 0–7 not anxious;
8–10 borderline; ≥11 case-level anxiety [25]); global cogni-
tive function was assessed using the Mini Mental State
Examination (MMSE; scored as 26–30 normal cognitive
function; 20–25 mild cognitive impairment; <20 moderate
cognitive impairment [26]). Mild and moderate cognitive
impairment groups were combined because of the small
number of men in the latter group. Participants for whom
data was unavailable were classified as “unspecified” for
each of these categories [22].
Men’s overall physical health was measured by sum-
ming the number of self-reported chronic illnesses from
the following list: heart attack, heart failure, angina;
stroke; diabetes; hypertension; high cholesterol; lung
disease; asthma; cataracts; cancer; Parkinson's disease;
peptic ulcer; arthritis; osteoporosis or hip fracture. Men
taking medications in the WHO-ATC category G04C
were classified as having been treated for Benign Pros-
tatic Hypertrophy (BPH). Previous cancer diagnosis
(yes/no) was identified separately. A frailty score was
derived within TILDA from five measurements; self-
reported weight-loss of ≥4.5 kg in the year pre-interview;
weakness based on grip-strength; self-reported exhaustion;
gait speed; and low physical activity. Other variables asso-
ciated with frailty were: self-reported arthritis, joint re-
placement and osteoporosis (yes/no), hip or wrist fracture
(ever/never). Subjective health status variables investigated
included overall self-rated health, and self-rated emotional
or mental health (excellent/very good, good, fair/poor).
Socio-demographic characteristics including age, mari-
tal status, work status, smoking status, highest educa-
tional level achieved and PHI status, were recorded at
the CAPI.
Statistical analysis
Univariate analyses (chi-square test, Wilcoxson rank-sum)
were used to identify associations between covariates and
ever having had a PSA test. Logistic regression was used
to build a multivariate model of predictors of PSA testing.
Analysis was conducted in two stages. Firstly, a core
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utilisation and health status variables previously associated
with PSA testing (age, marital status, education, employ-
ment, smoking status, number of GP visits) and covariates
with a p-value <0.1 in univariate analyses. Collinearity was
addressed by including one of two potentially correlated
variables (e.g. number of chronic illnesses, but not number
of medicines). Covariates retained in the core model were:
number of chronic illnesses, influenza vaccine, prior can-
cer diagnosis, treated for BPH, and GMS eligibility. In
stage two, psychological and physical health measures
were added separately to the core model, to assess their
independent association with PSA testing.
Sensitivity analysis was performed to examine effects
on multivariate risk estimates of PSA testing of exclud-
ing men who had a previous prostate cancer diagnosis
(n = 93). Individual comorbidities were assessed for asso-
ciation with PSA testing in the core model, as an add-
itional analysis.
TILDA data V 1-7-3 and STATA V 12 were used for
analyses. Significance at p < 0.05 was assumed.
Results
Study population characteristics
The median age of men was 63 years (IQR 56–71, N =
3,628). 68.2% reported ever having a PSA test (Table 1).
Of these men, 84.2% returned the SCQ, and HA data
was available for 72.3% (Figure 1).
Stage 1: Core model
The core multivariate model is presented in Table 2. Ever
having a cholesterol test was the factor most strongly asso-
ciated with PSA testing in univariate analysis (OR = 17.0
95%CI 12.9-22.4). Therefore, to assess other independent
associations with PSA testing, this variable was removed
from the model. In multivariate analyses, physical health
(more chronic conditions (OR = 1.11 per unit increase in
conditions, 95%CI 1.05-1.19); previous cancer diagnosis
(OR = 2.74, 95%CI 1.74-4.30); BPH treatment (OR = 2.66,
95%CI 1.65-4.27)), healthcare utilisation (increased number
of GP visits (OR = 1.01, 95%CI 1.01-1.05; having an influ-
enza vaccination (OR = 1.35, 95%CI 1.13-1.60)); and socio-
demographic variables (higher educational attainment and
being married/cohabiting compared to other marital sta-
tus) were associated with increased likelihood of having
PSA tests. Men were significantly less likely to have had
PSA tests if they were: current smokers (OR = 0.56, 95%CI
0.45-0.69), GMS eligible (OR = 0.63, 95%CI 0.52-0.77) or
were not employed (OR = 0.67, 95%CI 0.53-0.85) (Table 2).
Stage 2: associations between psychological and physical
health and PSA testing
One-fifth of these men had depression, of whom 15%
and 7% had sub-threshold and case-level depression,respectively. Prevalence of borderline and case-level anx-
iety were 16.3% and 5.4%, respectively. Men with sub-
threshold depression were significantly less likely to have
had a PSA test(s) (adjusted OR = 0. 79, 95%CI 0.62-0.97).
Men with case-level anxiety had reduced likelihood of
PSA testing in unadjusted analyses compared to non-
anxious men, but this was not significant following ad-
justment (OR = 0.79, 95%CI 0.57-1.09). Lower self-rated
emotional or mental health was associated with reduced
likelihood of PSA testing in univariate analysis, but this
was no longer significant in adjusted analyses (Table 3).
Patients with a degree of cognitive impairment were
significantly less likely to have had PSA tests. Those with
mild-moderate cognitive impairment were less likely to
have had PSA tests, compared to those with unimpaired
cognition, though non-significantly (OR = 0.79, 95%CI
0.58-1.08).
Frailty was associated with reduced likelihood of PSA
testing, this was significant for men who were pre-frail
(adjusted OR = 0.68, 95%CI 0.56-0.83). Individual frailty
measures associated with non-testing were low grip
strength (OR = 0.84, 95%CI 0.69-1.02), low gait speed
(OR = 0.61, 95%CI 0.43-0.86) and low levels of physical ac-
tivity (OR 0.66, 95%CI 0.50-0.87) (Additional file 2). Men
who reported heart attack/heart failure/angina (OR = 0.62,
95%CI 0.47-0.80), stroke (OR = 0.55, 95%CI 0.32-0.95) and
lung disease (OR = 0.64, 95%CI 0.43-0.95) were signifi-
cantly less likely to have had PSA tests in adjusted analyses
(Additional file 3).
Exclusion of men who had a prostate cancer diagnosis
(N = 93) did not affect associations between any covari-
ates in the core model and ever having a PSA test, ex-
cept previous cancer diagnosis (Additional file 4).
Discussion
PSA testing is widespread in Ireland. However, our find-
ings suggest that men with lower self-reported physical
and psychological health, including depression, anxiety,
cognitive impairment and frailty were less likely to have
had a PSA test, while men with very good self-reported
health were more likely to have had a PSA test, in this
nationally representative sample of men aged 50 years or
older, after adjusting for socio-demographic factors. In-
creased healthcare utilisation was also associated with
increased likelihood of PSA testing, however men who
were eligible for free healthcare were less likely to have
been tested.
These results should be interpreted with some care, as
the study was cross-sectional in design; however we con-
sidered three hypotheses of health behaviour to explain
these observations [27,28]. Firstly, there is evidence of a
‘healthy user effect’ [27] whereby men taking preventa-
tive medication e.g. statins and receiving influenza vacci-
nations were more likely to have had PSA tests. The
Table 1 Characteristics of the study population, stratified according to whether they ever or never had a PSA test
(N (%), unless otherwise stated)
Population characteristics PSA tested
Ever Never
N = 2,473 (68.2%) N = 1,153 (31.8%) p-value
Socio-demographic characteristics
Age at interview Years Median, (IQR) 64 (57, 71) 59 (54, 69) <0.001
Marital status Married N (%) 1,916 (77.4) 795 (69.0) <0.001
Single N (%) 248 (10.0) 178 (15.4)
Sep/Divorced N (%) 112 (4.5) 89 (7.7)
Widowed N (%) 199 (8.0) 91 (7.9)
Education Primary N (%) 771 (31.2) 425 (36.9) <0.001
Secondary N (%) 952 (38.5) 463 (40.2)
Third Level N (%) 752 (30.4) 265 (23.0)
Employment Employed N (%) 1,007 (40.7) 508 (44.1) <0.001
Retired N (%) 1,225 (49.5) 406 (35.2)
Other N (%) 243 (9.8) 239 (20.7)
Smoking status Never N (%) 919 (37.2) 374 (32.4) <0.001
Past N (%) 1,215 (49.1) 471 (40.8)
Current N (%) 340 (13.7) 308 (26.7)
PHI At time of CAPI N (%) 1,618 (65.4) 514 (44.6) <0.001
Health-care utilisation
No. of GP visits year pre-CAPI Median (IQR) 3 (1,5) 2 (0, 4) <0.001
Cholesterol test Ever N (%) 2,408 (97.4) 791 (68.9) <0.001
Influenza Vaccine Ever N (%) 1,352 (54.6) 468 (40.6) <0.001
No. of medicines Self-reported Median (IQR) 2 (0, 4) 1 (0, 3) <0.001
BPH-Medicine N (%) 166 (4.7) 21 (1.8) <0.002
Aspirin N (%) 673 (27.2) 216 (18.7) <0.001
Statin N (%) 869 (35.1) 277 (24.0) <0.001
GMS eligibility At time of CAPI N (%) 1,072 (43.3) 544 (47.2) 0.029
Physical, mental and emotional health
Overall health1 Excellent/Very good N (%) 1,398 (56.5) 601 (52.3) 0.012
Good N (%) 690 (27.9) 376 (32.7)
Fair/Poor N (%) 386 (15.6) 173 (15.0)
No. chronic illnesses Median (IQR) 2 (1, 3) 1 (0,2) <0.001
Cancer diagnosis Ever N (%) 179 (7.2) 24 (2.1) <0.001
Prostate cancer N (%) 93 (3.8) 0 (0) <0.001
Frailty Not frail N (%) 1,265 (51.1) 486 (42.2) <0.001
Pre-frail N (%) 481 (19.5) 244 (21.2)
Frail N (%) 57 (2.3) 23 (2.0)
Unrecorded N (%) 670 (27.1) 400 (34.7)
Emotional/Mental health1 Excellent/Very good N (%) 1,604 (64.8) 689 (59.8) 0.007
Good N (%) 676 (27.3) 347 (30.1)
Fair/Poor N (%) 195 (7.9) 117 (10.2)
Depression score CESD Median (IQR) 3 (0, 6) 3 (1, 8) 0.001
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Table 1 Characteristics of the study population, stratified according to whether they ever or never had a PSA test
(N (%), unless otherwise stated) (Continued)
Depression No N (%) 1,954 (79.9) 847 (74.6) 0.002
Sub-threshold N (%) 344 (14.1) 200 (17.6)
Case-Level N (%) 151 (6.2) 88 (7.8)
Anxiety score HADS-A (SCQ) Median (IQR) 4 (2, 7) 5 (2, 7) 0.167
Anxiety categorical Not anxious N (%) 1,679 (67.8) 695 (60.2) 0.001
Borderline N (%) 277 (11.2) 115 (10.0)
Case-Level N (%) 118 (4.8) 75 (6.5)
Unclassified N (%) 401 (16.2) 268 (23.2)
Cognition MMSE score Median (IQR) 29 (27, 30) 29 (28, 30)
MMSE categorical Normal N (%) 1,677 (67.8) 699 (60.6) <0.001
Mild /moderate Impairment N (%) 157 (6.3) 83 (7.2)
Unrecorded N (%) 641 (25.9) 371 (32.2)
1Self-rated overall and emotional or mental health relative to others of the same age; PHI: Private Health Insurance; CAPI: Computer Aided Personal Interview;
SCQ: self-completed questionnaire, IQR: Interquartile range.
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orating ‘health-seeking’ tendencies, i.e. healthier patients
request or accept more screening tests and have in-
creased adherence to medications, but it also incorpo-
rates ‘health status’ i.e. the ability of patients, physically
and cognitively to attend primary care and to get pre-
scriptions filled [27]. Multi-morbidity results in poly-
pharmacy and increased health services utilisation [29].
We found that, despite adjusting for number of GP
visits, men with more chronic illnesses were more likely
to have been tested, suggesting that some PSA tests can
be ascribed to the ‘surveillance hypothesis’ i.e. men with
coexisting conditions have more frequent contact with
the healthcare system facilitating early diagnosis [20,28].
However, while not the central focus of this paper, we
found that the association between comorbidity and
PSA testing depended on the coexisting disease, which
was in agreement with other studies [30]. In this cohort,
likelihood of PSA testing was increased in men with
angina, high cholesterol, cataracts and hypertension
(‘surveillance hypothesis’), but was negatively associated
with frailty, cardiac diseases and stroke, suggesting that
poorer physical health may distract a GP from under-
taking, or offering men a PSA test, the ‘competing de-
mand hypothesis’ [28].
The negative associations observed, in this cohort, be-
tween poorer psychological health and likelihood of PSA
testing are further evidence of the ‘competing demand
hypothesis.’ The impact of poor psychological health on
the likelihood of men having a PSA test has received lit-
tle attention. Men with sub-threshold depression were
significantly less likely to have PSA tests than men who
were not depressed, suggesting that somatic symptoms
associated with depression may be more pertinent dur-
ing healthcare visits, or that GPs may be less likely toinitiate discussions about PSA testing and prostate can-
cer with depressed men for fear of exacerbating their
condition [31]. Our findings concur with previous work
which observed lower rates of breast, cervical and colo-
rectal cancer screening among people with depression
[13,14,32], despite increased usage of primary care ser-
vices [14]. However, we found that case-level depression
was not associated with PSA testing. This may be due to
various reasons; men with case-level depression may be
receiving management for depression and thus may be
more likely to be PSA tested, consistent with the ‘sur-
veillance hypothesis’; the number of men with case-level
depression may be too small to detect significant effects;
or the effect of case-level depression on PSA testing may
be no longer significant when other aspects of psycho-
logical health e.g. anxiety was included in the model. In
support of the latter hypothesis, Kotwal et al. observed
that men with depressive symptoms were less likely to
have PSA tests however, this effect was mediated by
levels of perceived stress [19] which concurs with the
surveillance hypothesis. While stress was not measured
in this cohort, we found that case-level anxiety was asso-
ciated with reduced likelihood of PSA testing in univari-
ate, but not adjusted analysis.
Anxiety has been shown to influence PSA testing in a
number of ways. A review found variations in anxiety
levels across the prostate cancer continuum from screen-
ing to beyond treatment [16]. Dale et al., observed that
PSA screening was associated with increased levels of anx-
iety in men, highest in those with high pre-dispositional
anxiety, but this mostly subsided upon receipt of a normal
result [16]. Furthermore, anxiety about having prostate
cancer predicted both PSA testing and avoidance of
screening, the latter especially among asymptomatic men
with a family history of prostate cancer. To further
Figure 1 Flow diagram of the study population identified from the TILDA study.
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et al., in a small study of 533 American men, aged 45 to
70 years, investigated the effect of three components of
anxiety i.e. dispositional anxiety, prostate cancer worry,
and screening fear on frequency of PSA testing (and
digital rectal exams (DRE)) [18]. They concluded that can-
cer worry propelled men to have PSA tests, screening fear
deterred men from having DRE, but not PSA tests, and
trait anxiety was associated with more frequent DREs, but
not with PSA testing [18]. Furthermore, a recent study ob-
served that the association between anxiety and PSA test-
ing is dependent on the number of GP visits [19]; men
were less likely to be PSA tested if they had higher anxiety
and attended their GP once, but men with higher anxiety
who attended their GP more frequently were more likely
to be tested. However, it is difficult to draw comparisonsbetween studies due to different study designs, populations
examined and instruments used to measure psychological
health (depression, anxiety and stress) [13-16,18,19].
Men with increased cognitive impairment were also
significantly less likely to have had PSA tests, which
again may be explained by the ‘competing demands’ hy-
pothesis. This is the first time associations between psy-
chological health and PSA testing has been observed in
men in Ireland and our findings add to the growing
body of literature on the effect of psychological health
on preventative health and cancer screening.
Eligibility for free healthcare (GMS eligibility) is asso-
ciated with more frequent GP visits [23], however, des-
pite adjustment for socio-demographic, health, and
healthcare factors including number of GP visits, GMS
eligibility was negatively associated with PSA testing, which
Table 2 Univariate (OR 95% CI) and multivariate (OR 95% CI) analysis of associations between socio-demographic
characteristics, healthcare utilisation, and physical health, and ever having had a PSA test (Stage 1: Core Model)
Variables associated with PSA testing Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Socio-demographic factors
Age at interview Years 1.03 1.02-1.04 <0.001 1.02 1.00- 1.03 0.012
Marital status Married 1.00 Ref 1.00 Ref
Single 0.58 0.47-0.72 <0.001 0.69 0.55-0.87 0.001
Separated/Divorced 0.52 0.39-0.70 <0.001 0.68 0.50-0.92 0.014
Widowed 0.91 0.70-1.18 0.466 0.70 0.53-0.94 0.017
Education Primary 1.00 Ref 1.00 Ref
Secondary 1.13 0.96-1.33 0.131 1.31 1.09-1.57 0.004
Third Level 1.56 1.30-1.88 <0.001 1.49 1.22-1.83 <0.001
Employment Employed 1.00 Ref 1.00 Ref
Retired 1.52 1.30-1.78 <0.001 1.23 0.99-1.53 0.056
Other 0.51 0.42-0.63 <0.001 0.67 0.53-0.85 0.001
Smoking status Never 1.00 Ref 1.00 Ref
Past 1.05 0.89-1.23 0.553 0.96 0.81-1.14 0.634
Current 0.45 0.37-0.55 <0.001 0.56 0.45-0.69 <0.001
Private health insurance Yes 2.35 2.04-2.71 <0.001
Healthcare utilisation factors
Number of GP visits Continuous 1.04 1.02-1.06 <0.001 1.03 1.01-1.05 0.001
Influenza vaccine Ever 1.76 1.53-2.03 <0.001 1.35 1.13-1.60 0.001
GMS scheme eligible Yes 0.86 0.74-0.98 0.029 0.63 0.52-0.77 <0.001
Number of medicines Continuous 1.12 1.08-1.15 <0.001
Cholesterol test Yes 17.00 12.9-22.4 <0.001
Physical health
Chronic illnesses Continuous 1.25 1.19-1.32 <0.001 1.11 1.05-1.19 0.001
Prior cancer diagnosis Yes 3.66 2.38-5.64 <0.001 2.74 1.74-4.30 <0.001
Treated BPH Yes 3.87 2.45-6.14 <0.001 2.66 1.65-4.27 <0.001
Variables for which multivariate ORs are presented are those contained within the core model; Multivariate ORs are adjusted for age (continuous), marital status
(married/single/separated or divorced/widowed), highest education level attained (primary/secondary/third level), employment status (employed/retired/other),
smoking status (never/past/current), number of GP visits in the past year (continuous), receipt of influenza vaccine (ever/never), number of chronic illness reported
(continuous), GMS eligibility (yes/no), prior cancer diagnosis (yes/no) and reported receipt of medicines for BPH.
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PSA testing observed in Ireland and elsewhere [33]. This
highlights the issue that in mixed public-private sys-
tems, free healthcare services does not produce equity
in uptake of primary care services, and may in part ex-
plain the higher prostate cancer incidence in higher so-
cioeconomic groups [34].
Socio-demographic factors were strong predictors of
PSA testing and our findings are broadly in agreement
with others [19,20,33]. Married men were more likely to
have PSA tests possibly because their wives engage in
breast and cervical cancer screening (Drummond et al.
unpublished data). Odds of PSA testing were greatly re-
duced in current smokers, this trend concurs with findings
from previous studies [35]. Smoking-related illnesses maybe prioritised by GPs, the ‘competing demands hypothesis’
and/or smokers may avoid engagement with health ser-
vices because they anticipate unwanted advice to quit
smoking [36].
This study has several strengths. It is a large sample,
representative of the population [22], with data on a wide
range of variables. Standardised measures of depression,
anxiety and cognitive function were used, although stress
was not measured. We acknowledge several limitations;
data on PSA testing was self-reported, which is subject to
recall bias [37]. However, that more than two-thirds of
men reported ever having a PSA test is not surprising
given the level of PSA testing in Ireland has risen since
the mid 1990’s [38]; by 2004, 41.2% of men aged 50 years
and older had had a PSA test [6], and the number of PSA
Table 3 Univariate (OR 95% CI) and multivariate (OR 95% CI) analysis of associations between psychological and
physical health covariates, and ever having had a PSA test (Stage 2)
Physical, mental and emotional health Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Self-rated health Excellent/Very good 1.00 Ref 1.00 Ref
Good 0.79 0.67-0.92 0.003 0.78 0.66-0.93 0.005
Fair/Poor 0.96 0.78-1.18 0.688 0.88 0.69-1.38 0.320
Self-rated emotional/mental health Excellent/Very good 1.00 Ref 1.00 Ref
Good 0.84 0.72-0.98 0.026 0.91 0.77-1.08 0.258
Fair/Poor 0.72 0.56-0.92 0.008 0.82 0.62-1.08 0.158
Depression CES-D 0.98 0.97-0.99 0.002 0.99 0.98-1.00 0.126
Depression No 1.00 Ref 1.00 Ref
Sub-threshold 0.75 0.62-0.90 0.003 0.79 0.64-0.97 0.025
Case-level 0.74 0.56-0.98 0.035 0.85 0.62-1.15 0.293
Anxiety Continuous 0.98 0.96-1.00 0.078 1.00 0.97-1.02 0.791
Anxiety categorical Not anxious 1.00 Ref Ref 1.00
Borderline 0.99 0.79-1.26 0.980 1.02 0.79-1.30 0.906
Case-level 0.65 0.48-0.88 0.003 0.79 0.57-1.09 0.159
Unclassified 0.62 0.52-0.74 <0.001 0.71 0.59-0.87 0.001
Cognition: MMSE score Continuous 1.04 1.01-1.08 0.023 1.05 1.01-1.10 0.024
MMSE score for cognitive impairment Unimpaired 1.00 Ref 1.00 Ref
Mild-moderate 0.79 0.60-1.04 0.096 0.79 0.58-1.08 0.134
Unrecorded 0.72 0.62-0.84 <0.001 0.84 0.71-1.00 0.049
Frailty Not frail 1.00 Ref 1.00 Ref
Pre-frail 0.76 0.62-0.91 0.003 0.68 0.56-0.83 <0.001
Frail 0.95 0.58-1.56 0.846 0.61 0.35-1.05 0.072
Unrecorded 0.65 0.55-0.76 <0.001 0.72 0.60-0.85 <0.001
Arthritis 1.59 1.32-1.91 <0.001 1.23 0.99-1.52 0.058
Aspirin 1.62 1.36-1.92 <0.001 1.18 0.96-1.44 0.113
Statin 1.71 1.46-2.00 <0.001 1.28 1.06-1.54 0.009
Multivariate ORs are adjusted for the core model: adjusted for age (continuous), marital status (married/ single/separated or divorced/widowed), education level
attained (primary/secondary/ third level), employment status (employed/retired/other), smoking status (never/ past/current), number of GP visits in the past year
(continuous), receipt of influenza vaccine (ever/never), number of chronic illness reported (continuous), GMS eligibility (yes/no) prior cancer diagnosis (yes/no) and
reported receipt of medicines for BPH.
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may have been withheld e.g. use of anti-depressants; or
chronic conditions misclassified and the strength of
some associations with PSA testing may have been lim-
ited due to small numbers in sub-groups. A small num-
ber of men in this study (n = 93; 2.6%) had a previous
prostate cancer diagnosis, and the prevalence of psy-
chological distress (including depression and anxiety)
has been shown to be elevated in men with prostate
cancer in some studies [39,40], but not others [41].
Analyses were adjusted for previous cancer diagnosis
and a sensitivity analysis was conducted excluding men
with a previous prostate cancer diagnosis (Additional
file 4: Table S4). Finally, there is potentially residual or
unmeasured confounding in the analysis for examplethe influence of GPs, or ‘provider effect’, on whether
men were PSA tested.
Conclusions
In conclusion, this cross-sectional study provides insight
into the characteristics of men who have, and have not
had PSA tests in primary care. Men in poorer psycho-
logical and physical health, smokers and those eligible
for free GP services were less likely to have had PSA
tests while men in good overall health and those en-
gaging in health-seeking behaviours were more likely to
have been tested. These findings might be considered by
physicians and policy makers in the development of
public health strategies to improve the appropriateness
and equality of prostate cancer detection.
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Additional file 2: Table S2. Univariate (OR 95% CI) and multivariate (OR
95% CI) analysis of associations between covariates which make up the
frailty score, and ever having had a PSA test.
Additional file 3: Table S3. Post-hoc analysis; Univariate (OR 95% CI)
and multivariate (OR 95% CI) analysis of associations between chronic
illnesses and ever having had a PSA test.
Additional file 4: Table S4. Assessment of the association between
PSA testing (yes/no) and covariates associated with PSA testing having
excluded men with prior prostate cancer.
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